| Document |
Document Title |
|
WO/2024/097575A1 |
Provided are compounds of formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising c...
|
|
WO/2024/092316A1 |
An animal watering system is disclosed. The animal watering system comprises an activated water source and an animal watering station configured to receive activated water from the activated water source. The activated water source compr...
|
|
WO/2024/064895A3 |
The present disclosure relates to adeno-associated virus (AAV)-mediated delivery of nucleic acids for treating neuromuscular disorders, e.g., X-linked myotubular myopathy (XLMTM), in patients in need thereof. The AAV vectors of the discl...
|
|
WO/2024/095178A1 |
A method of treating patients suffering from acute liver failure is disclosed. The method comprises administering to a patient in need of treatment an effective amount of a thrombopoietin (TPO) compound alone or combined with another age...
|
|
WO/2024/097573A1 |
Provided are compounds of formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising...
|
|
WO/2024/059753A3 |
This disclosure relates to the once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same for inducing weight loss in a human being with fatty liver disease, wherein the human may or may not...
|
|
WO/2024/094841A1 |
Provided herein are methods for Alagille syndrome (ALGS) with an ileal bile acid transport (IBAT) inhibitor such as odevixibat, or a pharmaceutically acceptable salt thereof. Such methods can include reducing pruritus score, serum bile a...
|
|
WO/2024/096091A1 |
[Problem] To provide an agent which is safe even when ingested for a long period and can improve the intestinal microflora of a dog. [Solution] This agent for improving the intestinal flora of a dog contains nicotinamide mononucleotide a...
|
|
WO/2024/093910A1 |
Provided are an antiviral-based hand sanitizer and use thereof. The hand sanitizer possesses antibacterial and antiviral effects and a good killing effect against common bacteria and fungi such as Escherichia coli, Staphylococcus aureus,...
|
|
WO/2024/097138A1 |
Alternative splicing events in genes can lead to non-productive mRNA transcripts which in turn can lead to aberrant or reduced protein expression, and therapeutic agents which can target the alternative splicing events in the genes can m...
|
|
WO/2024/095013A1 |
The present disclosure relates to an oral product, a process for producing the oral product, as well as to uses of said oral product. The oral product comprises a combination of active ingredients, wherein the combination comprises: caff...
|
|
WO/2024/097436A1 |
Compounds for modulating the activity and/or the expression of 5-aminolevulinic acid synthase (ALAS) affecting biological functions. In part, novel compounds and pharmaceutically acceptable salts and in part, methods for preparing the no...
|
|
WO/2024/095268A1 |
Methods for treating or reducing inflammation, in is in a site or an organ excluding the central nervous system of a subject in need thereof, by administering a pharmaceutical composition comprising the translocator protein ligand 2-C1-M...
|
|
WO/2024/096014A1 |
The purpose of the present invention is to provide a novel TRPA1 agonist.　The present invention relates to a composition for activating TRPA1, comprising a mushroom extract or lenthionine. The composition can enhance appetite and food ...
|
|
WO/2024/096404A1 |
The present invention relates to a composition containing VER-246608 for the prevention, alleviation, or treatment of fatty liver disease. More specifically, VER-246608 allows for effectively inhibiting the accumulation of fat in hepatoc...
|
|
WO/2024/097247A1 |
The present invention relates to FXR agonist compounds and methods of use thereof for treating, ameliorating, or promoting recovery from diseases and disorders, such as acute diseases of the liver, for example, severe alcohol-associated ...
|
|
WO/2024/097576A1 |
Provided are compounds of Formula I, Formula Ib or Formula Ic and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, Formula Ib or ...
|
|
WO/2024/097875A1 |
The present disclosure relates to, inter alia, compositions and methods, including heterologous chimeric proteins that find use, inter alia, in the treatment of nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NAS...
|
|
WO/2024/090929A1 |
The present invention relates to a mixed composition and for inhibiting fat accumulation, including cassia seed sprouts and buckwheat sprouts, and a use thereof. The mixed composition of the present invention inhibits adipogenesis in pre...
|
|
WO/2024/091958A1 |
Provided herein are compositions, systems, and methods comprising guide nucleic acids and uses thereof with CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure may leverage the activitie...
|
|
WO/2024/090747A1 |
The present invention relates to a composition comprising cannabidiol and taurine for preventing or treating periodontitis. The composition according to the present invention can inhibit inflammatory factors and directly inhibit alveolar...
|
|
WO/2024/089177A1 |
The invention relates to SOCS1 derived isolated polypeptides and compositions comprising such polypeptides for use in the prevention, relief and/or treatment of an obesity related liver disorder or a pathological condition or disease cau...
|
|
WO/2024/089059A1 |
The invention concerns formula for based on extensively hydrolysed protein and/or free amino acids for allergic infants that are thickened with a combination of xanthan gum and locust bean gum.
|
|
WO/2024/089296A1 |
The present invention is directed to novel modulators of the Ca2+-signaling cascade, acting as potentiators of the P2RY2 purinergic receptor and of the inositol triphosphate receptors, ITPRs. The compounds are useful in the treatment of ...
|
|
WO/2024/091952A1 |
Disclosed herein are compositions comprising antioxidants and methods of use thereof.
|
|
WO/2024/088282A1 |
The present invention provides a pyridazine compound as shown in formula (II), a preparation method therefor, and uses thereof. Also disclosed are uses of the compound of the present invention or the pharmaceutical composition thereof in...
|
|
WO/2024/089582A1 |
The present disclosure encompasses solid state forms of Cilofexor and salts thereof, in embodiments crystalline polymorphs of Cilofexor and salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2024/090415A1 |
The present invention addresses the problem of providing lactic acid bacteria having high ability to activate innate immunity. The present invention also addresses the problem of providing: an innate immunity activator containing, as an ...
|
|
WO/2024/089262A1 |
The present invention provides a toothpaste composition comprising fluoride and poly gamma glutamic acid or a salt thereof, a toothpaste tablet and a method of making a toothpaste tablet, comprising the steps of a. providing the toothpas...
|
|
WO/2024/089060A1 |
The invention is in the field of thickened formulas for infants that suffer from regurgitation. In particular the infant formulas are thickened with a combination of xanthan gum and locust bean gum and comprise a mixture of specific nond...
|
|
WO/2024/090413A1 |
The present invention addresses the problem of providing a lactic acid bacterium having high natural immunoactivating capability. The present invention also addresses the problem of providing: a natural immunoactivator which contains, as...
|
|
WO/2024/088307A1 |
Disclosed are a novel peptidyl nitrile compound and a use thereof, and specifically disclosed are a compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound and/or th...
|
|
WO/2024/090926A1 |
The present invention relates to a composition containing illimaquinone for preventing, alleviating or treating fatty liver diseases. More specifically, illimaquinone can effectively inhibit fat accumulation of liver cells at low concent...
|
|
WO/2024/089260A1 |
The present disclosure provides a method of preventing, reducing, or ameliorating the symptoms of IBS, in a subject in need thereof, with L. plantarum. Further provided is L. plantarum for use in preventing, reducing, or ameliorating the...
|
|
WO/2024/088110A1 |
Provided are a heterocyclic macrocyclic compound containing an indazole structure and used as a protein kinase inhibitor, and a preparation method therefor. The compound has the structure represented by general formula (I). Additionally ...
|
|
WO/2024/091445A1 |
Provided herein are methods for treating cholestasis in a subject having liver disease. More specifically, the present invention relates to methods for treating Progressive Familial Intrahepatic Cholestasis (PFIC) in a subject where the ...
|
|
WO/2024/088712A1 |
The present invention relates to mGluR5 antagonists, or compounds 4-[5-[(rac)-1-[5-(3- Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol
-3-yl]pyridine (TT00), or a pharmaceutically acceptable salt thereof, enantiomer, isotope...
|
|
WO/2024/088364A1 |
The present disclosure relates to a pharmaceutical composition containing an isoquinolinone compound, and to a preparation method therefor. Specifically, the present disclosure provides a pharmaceutical composition containing 9,10-dimeth...
|
|
WO/2024/089229A1 |
The present invention is inter alia directed to pharmaceutical compositions or vaccines comprising lipid-based carriers, wherein the lipid-based carriers comprise RNA and are contained in a buffer system that comprises at least one polyo...
|
|
WO/2024/089061A1 |
The invention concerns formula for based on extensively hydrolysed protein and/or free amino acids for allergic infants that are thickened with a combination of xanthan gum and locust bean gum.
|
|
WO/2024/036157A9 |
|
|
WO/2024/090538A1 |
The present invention relates to a pharmaceutical composition for the treatment or prevention of inflammatory bowel diseases, said pharmaceutical composition containing zinc polyphosphate as an active ingredient. The zinc polyphosphate i...
|
|
WO/2024/090537A1 |
The present invention relates to a novel zinc polyphosphate, a use thereof, and a method for producing the same. More specifically, the present invention relates to: a zinc polyphosphate which is characterized by showing a halo peak at 2...
|
|
WO/2024/088190A1 |
Provided is an RNA inhibitor for inhibiting LPA gene expression or a pharmaceutically acceptable salt thereof. The RNA inhibitor is formed by base pairing of a sense strand and an antisense strand having a chain length of 15-30, and the ...
|
|
WO/2024/090800A1 |
A lipocalin 2 Inhibitor of the present invention can exhibit the effects of preventing and treating liver fibrosis by inhibiting the induction of liver cells into hepatic stellate cells through the inhibition of lipocalin 2 expression, a...
|
|
WO/2024/082638A1 |
Provided in the present invention is the use of dimetridazole in the preparation of a drug for treating feline diarrhea caused by Tritrichomonas foetus in cats, and also provided is a dimetridazole chewable tablet preparation.
|
|
WO/2024/083827A1 |
The present invention relates to a combination product comprising, as active substances, at least psyllium, baobab and acacia, for preventing and/or treating constipation or digestive disorders.
|
|
WO/2024/085081A1 |
Provided is an antibody that specifically binds to the extracellular domain of human LPA1 but does not specifically bind to the extracellular domain of human LPA2 or the extracellular domain of human LPA3. The antibody preferably has act...
|
|
WO/2024/084360A1 |
The present invention relates to compounds of Formula A, and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such proce...
|
|
WO/2024/085166A1 |
The present invention addresses the problem of: providing an anti-CLDN4-anti-CD137 bispecific antibody to be used in combination with a PD-1 signal inhibitor for treatment of a cancer, or a pharmaceutical composition comprising said bisp...
|
